Sun Pharma Recalls 2.7 Lakh Bottles Of Antidepressant, Says US Regulator
The recall is being initiated by Sun Pharmaceutical Industries Inc for 2,71,212 bottles of bupropion hydrochloride extended-release tablets, USP (SR) in the strengths of 150 mg and 200 mg, the... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pratham Investments Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kirit Valia Sun Pharma to announce third quarter results on February 14, 2017
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated January 31, 2017, titled "Sun Pharma to announce third quarter results on February 14, 2017". Q3 results on Feb 14, 2017
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 14, 2017, to consider and take on record the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2016 (Q3).In view of the consideration of above, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from February 03, 2017 to February 16, 2017 (both days inclusive). Sun Pharmaceutical Industries Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Sun Pharmaceutical Industries Ltd with respect to news appearing in CNBC TV 18 on January 23, 2017 titled "Sun Pharma to sell OHM labs site at New Jersey at $100M."Sun Pharmaceutical Industries Ltd response is enclosed. Sun Pharma to sell US arm Ohm Laboratories: Report
US market makes up half of Sun's revenue but business faces huge price erosion, regulatory issues
Sun Pharma may be selling its OHM labs unit in New Jersey
Sun Pharma - which has been reeling the past few months from FDA inspections of its factories and a subpoena in a price collusion case, as well as a severe fire at its Ahmednagar unit - may be selling its New Jersey based OHM labs for $100 million. The OHM labs site had come into Sun Pharma's hands with the Ranbaxy acquisition, and its not all been smooth sailing - Sun Pharma had to recall over a million bottles of anti-allergy medication Loratadine manufactured at the site in October 2015, after it was found that the drug was overpotent and not according to specifications. Sun Pharma had worked to overhaul the labs processes after the recall. Clarification sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd with respect to news article appearing on CNBC TV 18 on January 23, 2017 titled "Sun Pharma to sell OHM labs site at New Jersey at $100M." The reply is awaited. Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Sun Pharmaceutical Industries Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.